pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
GLP-1 receptor · news · pharmadog
← back to GLP-1 receptor
News · GLP-1 receptor
341
stories
6d
Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui
fiercebiotech
7d
Roche cans muscle-preserving obesity drug, hands it back to Chugai
endpoints
7d
STAT+: AbbVie wins FDA nod for Parkinson’s pill
stat
7d
STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more
stat
7d
Trump uses ‘contested’ power to cut more funding to HHS
stat
7d
Roche drops muscle-sparing obesity antibody after flunked interim analysis
fiercebiotech
7d
STAT+: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’
stat
8d
CDER director, expert discuss scientific, legal challenges to bringing generic GLP-1s to market
raps
10d
This week in charts: Novo’s rise and fall and AI biotechs’ big haul
biopharma dive
10d
Novo inks $1.3B Nanexa deal to unlock long-acting obesity injectables
fiercebiotech
11d
Pioneer of China NewCo model sued in US over trade secret misuse, double-dealing
fiercebiotech
11d
FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’
biospace
11d
Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalry
biospace
11d
Lilly puts up $100M, plus billions on the backend, to form 5-target deal with China's InnoCare
fiercebiotech
12d
Enveda, an AI drugmaker, banks $311M in venture funding
biopharma dive
12d
AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease push
biospace
12d
STAT+: Pharmalittle: We’re reading about a closing loophole for importing meds, European competitiveness, and more
stat
12d
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
biospace
13d
Compounder Empower receives FDA warning letter over GLP-1s
endpoints
13d
Viking shares surge on updated obesity drug data
biopharma dive
13d
Viking achieves 'maintenance trifecta' as GLP-1/GIP dual agonist exceeds expectations
biospace
13d
Novo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030
biospace
13d
Lilly presents early data supporting GLP-1/GIP candidate's potential in depression, alcohol use disorder
biospace
13d
Novo’s workforce reduction climbs to 13,000 to fuel R&D work
biospace
13d
Roche’s Carmot asset normalizes blood sugar, cuts weight in Phase 2 diabetes trial
biospace
13d
Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes
fiercebiotech
14d
Novo talks up drug launches in effort to win back investors
biopharma dive
14d
Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting
biospace
14d
STAT+: Pharmalittle: We’re reading about Novo plans to expand its pipeline, early Alkermes ADHD data, and more
stat
14d
Novo buys three early-stage obesity assets from Kallyope as investor pressure mounts
biospace
← prev
page 2 of 12
next →
